What is the first line therapy for demyelinating neuropathy with positive NF-155 antibodies?

Neurofascin-155 IgG antibody-associated neuropathy is a subtype of neuropathy with electrophysiologic features suggestive of demyelination, but distinctly different pathogenesis from classic CIDP, and also distinctly different response to treatments. Unlike CIDP where the target of the immune attack is the Schwan cell and where macrophage-mediated demyelination is present on nerve biopsies, in NF-155 IgG neuropathy, the antibodies target the paranodal Schwann cell loops and cause detachment from...